{"product_id":"cjc-1295-ipamorelin","title":"CJC-1295 + Ipamorelin","description":"\u003ch2\u003eAbout CJC-1295 + Ipamorelin\u003c\/h2\u003e\n\u003cp\u003eThis is a combination vial holding two synthetic peptides co lyophilized together: CJC-1295 without DAC, a 29 residue analogue of growth hormone releasing factor, and Ipamorelin, a pentapeptide secretagogue acting at a separate receptor. Both are supplied as a single powder cake, so laboratories studying the two receptor pathways receive them in a fixed documented ratio. Each component is synthesised and characterised separately before blending. Peptsche supplies CJC-1295 + Ipamorelin strictly as a research material for controlled laboratory investigation.\u003c\/p\u003e\n\n\u003ch3\u003eAvailable Sizes\u003c\/h3\u003e\n\u003cp\u003eOffered in one combination vial, sealed with a butyl closure and crimp.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e5 mg CJC-1295 without DAC and 5 mg Ipamorelin, co lyophilized in one vial\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eProduct Specifications\u003c\/h3\u003e\n\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProduct\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCJC-1295 without DAC and Ipamorelin blend, research grade lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIn vitro and laboratory research use only. Not for human or veterinary use.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAppearance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWhite to off white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eComposition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCJC-1295 without DAC 5 mg and Ipamorelin 5 mg, co lyophilized in a single vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eChemical Formula (CJC-1295)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eC\u003csub\u003e152\u003c\/sub\u003eH\u003csub\u003e252\u003c\/sub\u003eN\u003csub\u003e44\u003c\/sub\u003eO\u003csub\u003e42\u003c\/sub\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMolecular Weight (CJC-1295)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e3367.9 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCAS Number (CJC-1295)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePending verification. Public chemical registries currently disagree on the assignment for the form without DAC, so Peptsche does not publish a CAS number for this product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePubChem CID (CJC-1295)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/56841945\" target=\"_blank\" rel=\"noopener\"\u003e56841945\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSequence (CJC-1295)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTyr D-Ala Asp Ala Ile Phe Thr Gln Ser Tyr Arg Lys Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu Ser Arg NH2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eChemical Formula (Ipamorelin)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eC\u003csub\u003e38\u003c\/sub\u003eH\u003csub\u003e49\u003c\/sub\u003eN\u003csub\u003e9\u003c\/sub\u003eO\u003csub\u003e5\u003c\/sub\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMolecular Weight (Ipamorelin)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e711.9 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCAS Number (Ipamorelin)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e170851-70-4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePubChem CID (Ipamorelin)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/9831659\" target=\"_blank\" rel=\"noopener\"\u003e9831659\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSequence (Ipamorelin)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAib His D-2-Nal D-Phe Lys NH2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCJC-1295 no DAC and Ipamorelin blend, GHRH and GHRP combination vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e99% or greater by HPLC, verified per batch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStore sealed at 2 to 8 °C, protected from heat, light and moisture\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch use blend. Neither component is approved for human or veterinary use in any jurisdiction. Both CJC-1295 and ipamorelin appear on United States Food and Drug Administration bulk drug substances listings as substances withdrawn from consideration or presenting potential safety risks.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\n\u003ch2\u003eWhat is CJC-1295 + Ipamorelin?\u003c\/h2\u003e\n\u003cp\u003eThe two molecules belong to different chemical and pharmacological classes. CJC-1295 without DAC reproduces the active amino terminal fragment of hypothalamic growth hormone releasing factor, modified at four positions to resist cleavage. Ipamorelin is a synthetic pentapeptide of unnatural residues, designed as a selective ligand at the ghrelin receptor rather than as an analogue of an endogenous peptide.\u003c\/p\u003e\n\u003cp\u003ePresenting both in one vial is a convenience for laboratories exposing a preparation to two ligands at a fixed ratio without weighing each separately. Because the components are co lyophilized the ratio cannot be varied, trading flexibility for consistency between experiments.\u003c\/p\u003e\n\u003cp\u003ePublished work on this combination is sparser than the literature on either molecule alone. The references below characterise the individual components. No cited study examined the two together as a blend, so inferences about combined behaviour are extrapolation rather than observation.\u003c\/p\u003e\n\n\u003ch2\u003eCJC-1295 + Ipamorelin Mechanism of Action (Research Only)\u003c\/h2\u003e\n\u003cp\u003eInterest in this preparation rests on two components engaging separate receptors that converge on one pituitary cell type.\u003c\/p\u003e\n\n\u003ch3\u003eGrowth Hormone Releasing Factor Receptor Pathway\u003c\/h3\u003e\n\u003cp\u003eThe CJC-1295 component binds the growth hormone releasing factor receptor on anterior pituitary somatotrophs, a class B G protein coupled receptor signalling through the stimulatory G protein and raising cyclic adenosine monophosphate. Four substitutions limit cleavage by dipeptidyl peptidase, so the ligand persists longer in serum than the native fragment.\u003c\/p\u003e\n\n\u003ch3\u003eGhrelin Receptor GHS-R1a Pathway\u003c\/h3\u003e\n\u003cp\u003eIpamorelin binds the growth hormone secretagogue receptor GHS-R1a, a class A receptor coupling to the Gq protein and mobilising intracellular calcium through phospholipase C. Its selectivity is what made it notable in the original characterisation: it engages this receptor without the cross reactivity of earlier secretagogues in the same family.\u003c\/p\u003e\n\n\u003ch3\u003eRationale for Combined Study Designs\u003c\/h3\u003e\n\u003cp\u003eBecause the two receptors act through different second messenger systems in the same cell, investigators have used ligand pairs of this kind to ask whether responses are additive, synergistic or mutually limiting. A blend gives a fixed ratio starting point. The confounder is unequal persistence of the components, so occupancy at the two sites does not track together over a time course.\u003c\/p\u003e\n\n\u003ch3\u003eIntegrated Mechanistic Profile\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTwo receptor pathways:\u003c\/strong\u003e growth hormone releasing factor receptor agonism alongside ghrelin receptor GHS-R1a agonism.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDistinct signalling:\u003c\/strong\u003e cyclic nucleotide signalling from one component, calcium mobilisation from the other.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLimited combination data:\u003c\/strong\u003e published evidence on the blend is sparser than on either component alone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e CJC-1295 + Ipamorelin is supplied strictly for research use only. It is intended as an experimental compound for qualified laboratory personnel and is not a drug, food or cosmetic.\u003c\/p\u003e\n\u003cp\u003eCJC-1295 + Ipamorelin is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Applications (Observations from Studies)\u003c\/h2\u003e\n\u003cp\u003eThe summaries below describe published research on the individual components. They are not statements about the blend offered for sale.\u003c\/p\u003e\n\n\u003ch3\u003eReceptor Selectivity Characterisation\u003c\/h3\u003e\n\u003cp\u003eThe original description of Ipamorelin established it as a selective secretagogue receptor ligand in preclinical models, distinguishing it from earlier compounds in the same chemical series.\u003c\/p\u003e\n\n\u003ch3\u003ePreclinical Model Work\u003c\/h3\u003e\n\u003cp\u003eLater work examined the pentapeptide in rodent models to characterise skeletal endpoints, a reference point for laboratories designing comparable studies.\u003c\/p\u003e\n\n\u003ch3\u003eComparative Ligand Studies\u003c\/h3\u003e\n\u003cp\u003eThe growth hormone releasing factor analogue has been characterised in receptor expressing systems, giving binding and signalling parameters against which blend behaviour can be assessed.\u003c\/p\u003e\n\n\u003cp\u003eCJC-1295 + Ipamorelin is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eCJC-1295 + Ipamorelin Compared With Related Research Compounds\u003c\/h2\u003e\n\u003cp\u003eThe table below places CJC-1295 + Ipamorelin alongside two related compounds in the Peptsche range. It is offered to clarify differences in classification, molecular target and research context. It should not be read as a comparison of clinical performance, safety, or suitability for any application.\u003c\/p\u003e\n\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCharacteristic\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCJC-1295 + Ipamorelin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003ca href=\"\/products\/cjc-1295\"\u003eCJC-1295\u003c\/a\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003ca href=\"\/products\/ipamorelin\"\u003eIpamorelin\u003c\/a\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eResearch Classification\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTwo component co lyophilized research blend\u003c\/td\u003e\n\u003ctd\u003eSynthetic 29 residue analogue of growth hormone releasing factor\u003c\/td\u003e\n\u003ctd\u003eSynthetic pentapeptide growth hormone secretagogue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Molecular Target\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGrowth hormone releasing factor receptor and ghrelin receptor GHS-R1a\u003c\/td\u003e\n\u003ctd\u003eGrowth hormone releasing factor receptor on pituitary somatotrophs\u003c\/td\u003e\n\u003ctd\u003eGhrelin receptor GHS-R1a on pituitary somatotrophs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMechanistic Profile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBoth receptor systems engaged together, cyclic nucleotide signalling alongside calcium mobilisation\u003c\/td\u003e\n\u003ctd\u003eAgonism at the growth hormone releasing hormone receptor, with a brief plasma profile\u003c\/td\u003e\n\u003ctd\u003eAgonism at the ghrelin receptor GHS-R1a, a receptor system separate from the growth hormone releasing hormone receptor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Research Focus\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCombined ligand study designs across two receptor pathways\u003c\/td\u003e\n\u003ctd\u003eReceptor pharmacology, comparative stability and analytical method development\u003c\/td\u003e\n\u003ctd\u003ePituitary cell and receptor assays, rodent skeletal endpoints, comparative secretagogue pharmacology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStructural Design\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTwo peptides in one vial at a fixed ratio, no single formula or CAS number\u003c\/td\u003e\n\u003ctd\u003e29 residues with four substitutions, no albumin binding moiety\u003c\/td\u003e\n\u003ctd\u003eFive residues including non standard Aib and D configured aromatic residues, amidated terminus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch use blend, neither component approved for human or veterinary use in any jurisdiction, and both components appear on United States Food and Drug Administration bulk drug substances listings\u003c\/td\u003e\n\u003ctd\u003eResearch use compound, not approved for human or veterinary use in any jurisdiction, and withdrawn from consideration on the United States Food and Drug Administration bulk drug substances list\u003c\/td\u003e\n\u003ctd\u003eResearch use compound, not approved for human or veterinary use in any jurisdiction, and placed in Category 2 of the United States Food and Drug Administration list of bulk drug substances\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\u003cp\u003eCJC-1295 + Ipamorelin is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eLaboratory Handling and Storage Considerations\u003c\/h2\u003e\n\u003cp\u003eA co lyophilized blend behaves as one powder cake but contains two molecules of different physical properties, so partial withdrawal cannot be assumed to preserve the stated ratio. Treat the vial as a single unit and take it fully into solution before use. Sealed vials are stable at 2 to 8 °C when kept dry and dark, and should reach ambient temperature before opening so condensation does not form.\u003c\/p\u003e\n\u003cp\u003eIn solution both components degrade faster than in the dry state, and the two do not degrade at the same rate. Solutions should be sterile filtered, refrigerated, protected from light and used within a window the laboratory sets by its own testing. Aliquot into single use portions.\u003c\/p\u003e\n\n\u003ch3\u003eLaboratory Safety Considerations\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePersonal protective equipment:\u003c\/strong\u003e laboratory coat, nitrile gloves and eye protection whenever the vial is open.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEngineering controls:\u003c\/strong\u003e handle open vials inside a certified fume hood or containment enclosure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExposure prevention:\u003c\/strong\u003e avoid contact with skin and eyes, do not inhale the powder, never pipette by mouth.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e keep sealed at 2 to 8 °C, protected from heat, light and moisture, in a restricted area.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpill response:\u003c\/strong\u003e restrict access, avoid raising dust, collect with a damp wipe, then decontaminate and seal the waste.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDisposal:\u003c\/strong\u003e treat unused material and contaminated consumables as chemical laboratory waste under institutional rules.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDocumentation:\u003c\/strong\u003e record lot number, receipt date, storage conditions and quantities used for traceability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCertificate of Analysis and Quality Assurance\u003c\/h2\u003e\n\u003cp\u003eEvery production lot of CJC-1295 + Ipamorelin supplied by Peptsche undergoes analytical evaluation, and a batch specific Certificate of Analysis accompanies each order to support research documentation, quality control and experimental consistency.\u003c\/p\u003e\n\u003cp\u003eEach Certificate of Analysis typically includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIdentity verification\u003c\/strong\u003e using analytical techniques such as mass spectrometry to confirm the molecular characteristics of the material supplied.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity analysis\u003c\/strong\u003e performed by high performance liquid chromatography to quantify purity and identify potential impurities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBatch documentation\u003c\/strong\u003e recording lot number, testing date, analytical methods applied and quality assessment results.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTraceability information\u003c\/strong\u003e to support laboratory recordkeeping and reproducibility across research workflows.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePeptsche works with Janoshik Analytical, an independent testing laboratory, for third party verification of research material quality. Independent testing provides transparency and confidence in product identity, consistency and sourcing, and batch specific documentation can be retained as part of laboratory records and internal quality procedures.\u003c\/p\u003e\n\u003cp\u003eCJC-1295 + Ipamorelin is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is CJC-1295 + Ipamorelin?\u003c\/h3\u003e\n\u003cp\u003eCJC-1295 + Ipamorelin is a combination vial holding two synthetic peptides co lyophilized together: CJC-1295 without DAC, a 29 residue analogue of growth hormone releasing factor, and Ipamorelin, a pentapeptide secretagogue acting at a separate receptor. Each component is synthesised and characterised separately before blending. The two are supplied as a single powder cake in a fixed documented ratio.\u003c\/p\u003e\n\u003ch3\u003eWhat is CJC-1295 + Ipamorelin studied for in research?\u003c\/h3\u003e\n\u003cp\u003ePublished work on this combination is sparser than the literature on either molecule alone, and the cited references characterise the individual components. Those cover receptor selectivity characterisation, preclinical model work and comparative ligand studies. No cited study examined the two together as a blend, so inferences about combined behaviour are extrapolation rather than observation.\u003c\/p\u003e\n\u003ch3\u003eHow does CJC-1295 + Ipamorelin work in laboratory research?\u003c\/h3\u003e\n\u003cp\u003eThe CJC-1295 component binds the growth hormone releasing factor receptor on anterior pituitary somatotrophs, a class B G protein coupled receptor raising cyclic adenosine monophosphate. The Ipamorelin component binds the ghrelin receptor GHS-R1a, a class A receptor mobilising intracellular calcium through phospholipase C. Investigators have used ligand pairs of this kind to ask whether responses in a given preparation are additive, synergistic or mutually limiting.\u003c\/p\u003e\n\u003ch3\u003eHow is the quality of Peptsche CJC-1295 + Ipamorelin verified?\u003c\/h3\u003e\n\u003cp\u003eEvery production lot of Peptsche CJC-1295 + Ipamorelin is evaluated analytically, with identity confirmed using techniques such as mass spectrometry and purity quantified by high performance liquid chromatography. Peptsche works with Janoshik Analytical, an independent testing laboratory, for third party verification, and a batch specific Certificate of Analysis accompanies each order.\u003c\/p\u003e\n\u003ch3\u003eHow should unopened CJC-1295 + Ipamorelin be stored?\u003c\/h3\u003e\n\u003cp\u003eUnopened vials should be stored sealed at 2 to 8 °C, protected from heat, light and moisture. Vials should reach ambient temperature before opening so condensation does not form on the cold powder. Lot number, receipt date and storage conditions should be recorded in laboratory documentation so results stay traceable to a batch.\u003c\/p\u003e\n\u003ch3\u003eIs CJC-1295 + Ipamorelin intended for human use?\u003c\/h3\u003e\n\u003cp\u003eNo. CJC-1295 + Ipamorelin is supplied strictly for laboratory research use only. It is not approved for human consumption, veterinary use, diagnosis, treatment or any medical application.\u003c\/p\u003e\n\u003ch3\u003eWhy do researchers choose Peptsche for CJC-1295 + Ipamorelin?\u003c\/h3\u003e\n\u003cp\u003ePeptsche supplies this blend at 99% or greater purity by HPLC, verified per batch, with each component synthesised and characterised separately before blending. Certificates report identity of both components and confirmation of the stated ratio, and independent third party confirmatory analysis supports reproducibility across research workflows.\u003c\/p\u003e\n\n\u003ch2\u003eScientific References\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eJetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052 to 3058. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15817669\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/15817669\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eRaun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552 to 561. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9849822\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/9849822\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eJohansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone and IGF Research. 1999;9(2):106 to 113. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10373343\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/10373343\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2\u003eRESEARCH USE ONLY\u003c\/h2\u003e\n\u003cp\u003eThese compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.\u003c\/p\u003e","brand":"Peptsche","offers":[{"title":"5+5mg","offer_id":43752787476543,"sku":"PEP-CJCIPA-55MG","price":70.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/7394\/0287\/files\/peptsche_CJC1295Ipamorelin_55mg.png?v=1786904254","url":"https:\/\/peptsche.com\/products\/cjc-1295-ipamorelin","provider":"Peptsche","version":"1.0","type":"link"}